Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company ...
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past 100 ...
WindTree Therapeutics has the clinical results it wants—but is missing the bull market, meaning the biotech is exploring strategic options. Amid the market downturn, the biotech is considering a ...
Hosted on MSN
Windtree Therapeutics Cuts Preferred Stock by Over 99% Ahead of Crypto Strategy Rollout
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced major reductions in its outstanding Series C and Series D preferred shares, positioning the company to limit future equity ...
WARRINGTON, Pa., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (OTCID: WINT), a diversified company with several divisions and focused on becoming a ...
WARRINGTON, Pa., March 31, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device ...
Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher by 36.5% to $2.03 during Monday’s session after the company regained compliance with Nasdaq’s minimum bid price requirement, ensuring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results